CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF

Documenti analoghi

• Determinants of HBeAg loss during follow‐up of a multiethnic pediatric cohort
  di: David Mutimer, et al.
  Pubblicazione: (2024)
• A Genetic Variant of TLR6 Predicts HBsAg Decline After Pegylated Interferon‐Alpha Treatment in HBeAg‐Positive Chronic Hepatitis B
  di: Wanting Zeng, et al.
  Pubblicazione: (2026)
• Letter to the Editor Regarding Determinants of HBeAg Loss During Follow‐Up of a Multiethnic Pediatric Cohort
  di: Chia‐Ming Chu, et al.
  Pubblicazione: (2024)
• Unraveling the Role of Mutations Outside the Basal Promoter and Precore Regions in the HBeAg‐Negative Stage of Chronic Hepatitis B
  di: María Mercedes Elizalde, et al.
  Pubblicazione: (2025)
• Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B
  di: Hyunjae Shin, et al.
  Pubblicazione: (2024)